



Jason Murata

Partner

San Francisco

TEL 415.490.1487

jmurata@axinn.com

PRACTICE AREAS

Biotechnology
Intellectual Property
Patents
Trade Secret, Trademark & Copyright

EDUCATION

JD – Washington University School of Law (2002)

MA, Biology – Washington University (2002)

BS, Biochemistry – McMaster University (1999)

ADMISSIONS

California

Connecticut

Illinois

New York

U.S. Court of Appeals for the Federal Circuit

U.S. District Court Northern District of Illinois

U.S. District Court Northern District of California

PROFILE

Jason Murata is a partner in the intellectual property litigation group and chair of Axinn's Diversity, Equity & Inclusion Committee. Jason's practice involves all aspects of pre-trial, trial and appeals, with a particular focus on the pharmaceutical and biopharmaceutical, technology, consumer products, and food industries. He also brings extensive litigation experience to bear on complex issues relating to managing a company's IP risks and freedom to operate.

PROFESSIONAL ACTIVITIES


- American Intellectual Property Law Association, Committee on Nominations (2024)
- American Intellectual Property Law Association, Committee on the Profession
- American Bar Association, Section of Intellectual Property Law

EXPERIENCE

- *Mayne Pharma Int'l Pty Ltd. v. Merck & Co., Inc.*, No. 15-cv-00438 (D. Del.) (patent infringement action relating to Merck's Noxafil posaconazole products)
- *Globus Medical, Inc. v. DePuy Synthes Products, LLC*, No. 13-cv-00854 (D. Del.) (defend patent infringement action relating to spinal fusion implants)
- *Otsuka Pharmaceutical Co., Ltd. v. Zydus Pharmaceuticals USA Inc.*, Nos. 14-cv-03158-JBS-KMW & 14-cv-07252-JBS-KMW (D.N.J.) (obtained denial of motion for temporary restraining order in patent infringement action relating to generic aripiprazole drug)

product (Abilify))

- *Pfizer, Inc. v. Tiger Pharmaceuticals, LLC*, No. 14-cv-01501-AJT-TRJ (E.D. Va.); *Pfizer, Inc. v. Tiger Pharmaceuticals, LLC*, No. 14-cv-08958-GHW (S.D.N.Y.); *Johnson Matthey Inc. v. Pfizer, Inc.*, 2:15-cv-00014-AWA-TEM (E.D. Va.) (obtained dismissal of patent infringement action relating to dofetilide drug product within four months of filing of the action)
- *Depomed, Inc. v. Actavis Elizabeth LLC*, No. 3:12-cv-01358 (D.N.J.) and Appeal No. 14-1828 (Fed. Cir.) (bench trial in patent infringement action relating to generic once-daily gabapentin product)
- *The Procter & Gamble Co. v. Conopco, Inc.*, No. 13-CV-00732-TSB (S.D. Ohio) (represented Unilever in patent infringement action relating to antidandruff shampoo products)
- *Brandeis University v. Unilever United States, Inc.*, No. 12-cv-01510 (N.D. Ill.) (Posner, J.) (represented Unilever in patent infringement action brought by marketer of SmartBalance products relating to margarines and buttery spreads)
- *Hospira, Inc. v. Sun Pharmaceutical Industries, Inc.*, No. 2:10-cv-14514 (BAF/MJH) (E.D. Mich.) (defense of patent infringement action relating to generic dexemetomidine drug product)
- *Tyco Healthcare Group LP, et al. v. Mutual Pharmaceutical Co., Inc., et al.*, Civil Action No. 07-cv-1299 (D.N.J.) and Appeal No. 2010-1513 (Fed. Cir.) (obtained summary judgment of invalidity that asserted patent was obvious, which was affirmed by Federal Circuit)
- *In re Gabapentin Patent Litigation*, MDL No. 1384, Master Civil Action No. 00-2931 (D.N.J.) (patent infringement dispute involving gabapentin)
- *Aventis Pharmaceuticals Inc., et al. v. Sun Pharma Global Inc., et al.*, Civil Action Nos. 09-cv-00325 & -05179; Civil Action No.: 2:09-cv-5179-JAG (D.N.J.) (patent infringement dispute involving fexofenadine and fexofenadine / pseudoephedrine products)
- *Roche Palo Alto LLC. v. Endo Pharmaceuticals Inc.*, Civil Action No. 10-cv-00261-GMS (D. Del.) (patent infringement dispute involving valganciclovir hydrochloride)
- *United States Gypsum Co. v. Lafarge North America, Inc., Lafarge S.A., et al.*, Civil Action No. 03-CV-6027 (N.D. Ill. 2003) (theft of confidential, proprietary and trade secret information and patent



infringement involving gypsum drywall manufacturing)

- *Pall Corp. v. Entegris, Inc.*, Civil Action No. 07-CV-1869 (E.D.N.Y. 2007) (infringement dispute concerning filter media packing and capsule design)
- *Pall Corp. v. Entegris, Inc.*, Civil Action No. 05-CV-5894 (E.D.N.Y. 2005) (patent infringement dispute involving filter assembly methods and pre-wet packaging)
- *Entegris, Inc. v. Pall Corp.*, Appeal Nos. 2004-1440, 2005-1265, -1266, 2006-1374 (Fed. Cir. 2006) (appeal from preliminary injunction and contempt order in patent infringement dispute concerning filter assembly)
- *AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc.*, Appeal No. 04-1100 (Fed. Cir. 2004) (appeal in pharmaceutical case relating to generic extended-release felodipine tablets)
- *Ciba Specialty Chemicals Corp. v. Zinkan Enterprises Inc., et al.*, Civil Action No. C2 03 174 (S.D. Ohio 2002) (patent infringement dispute involving treatment of wastewater from coal mining)

HONORS

- *Profiles in Diversity Journal* Asian Leadership Award Winner (2023)
- New Leaders in the Law – *Connecticut Law Tribune* (2014)

